EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma

Erica Nakajima, Paul Leger, Ingrid A Mayer, Michael N Neuss, David D Chism, W Kimryn Rathmell

Kidney Cancer · 2017

DOI: 10.3233/kca-160004 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Kidney Cancer, 2017. Verfasst von Erica Nakajima und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report a case of severe type B lactic acidosis (LA) in a 51-year-old male, 12 days after he received his first dose of nivolumab for metastatic Von Hippel Lindau ( VHL)-mutated, clear cell renal cell carcinoma. Throughout his hospital course, infection, hypoperfusion, and tissue necrosis were not identified. We propose that his LA may have resulted from either inherent tumor glycolysis or immune activation and enhanced metabolism. The patient’s course was complicated by acute renal failure, and his LA rose progressively, eventually necessitating daily hemodialysis (HD). After receiving five consecutive days of HD, the patient started everolimus daily with the intent of reducing glycolytic metabolism. Subsequently, the rate of lactic acid production slowed, and HD was no longer required after two doses of everolimus. To our knowledge, this is the first reported case of type B LA following nivolumab administration, and the use of everolimus to treat type B LA in a patient with renal cancer.

Schlagwörter

Stichwörter der Autor:innen

Renal cell carcinomaacidosiseverolimus

Autor:innen und Institutionen

  • Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Nakajima, E., Leger, P., Mayer, I. A., Neuss, M. N., Chism, D. D., & Rathmell, W. K. (2017). A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. Kidney Cancer. https://doi.org/10.3233/kca-160004

Vancouver

Nakajima E, Leger P, Mayer IA, Neuss MN, Chism DD, Rathmell WK. A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. Kidney Cancer. 2017. doi:10.3233/kca-160004

BibTeX
@article{Nakajima2017,
  author = {Nakajima, Erica and Leger, Paul and Mayer, Ingrid A and Neuss, Michael N and Chism, David D and Rathmell, W Kimryn},
  title = {A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma},
  journal = {Kidney Cancer},
  year = {2017},
  doi = {10.3233/kca-160004}
}
Kostenlos starten →